CN113164595A - 抗人cd45rc抗体及其用途 - Google Patents

抗人cd45rc抗体及其用途 Download PDF

Info

Publication number
CN113164595A
CN113164595A CN201980076451.4A CN201980076451A CN113164595A CN 113164595 A CN113164595 A CN 113164595A CN 201980076451 A CN201980076451 A CN 201980076451A CN 113164595 A CN113164595 A CN 113164595A
Authority
CN
China
Prior art keywords
seq
antibody
binding fragment
lcvr
hcvr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980076451.4A
Other languages
English (en)
Chinese (zh)
Inventor
C·吉永瑙
I·阿内贡
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Nantes Université
Original Assignee
Universite de Nantes
Institut National de la Sante et de la Recherche Medicale INSERM
Centre Hospitalier Universitaire de Nantes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universite de Nantes, Institut National de la Sante et de la Recherche Medicale INSERM, Centre Hospitalier Universitaire de Nantes filed Critical Universite de Nantes
Publication of CN113164595A publication Critical patent/CN113164595A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/289—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD45
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Transplantation (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980076451.4A 2018-09-21 2019-09-20 抗人cd45rc抗体及其用途 Pending CN113164595A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP18306230.6 2018-09-21
EP18306230.6A EP3626265A1 (en) 2018-09-21 2018-09-21 Anti-human cd45rc antibodies and uses thereof
PCT/EP2019/075374 WO2020058495A1 (en) 2018-09-21 2019-09-20 Anti-human cd45rc antibodies and uses thereof

Publications (1)

Publication Number Publication Date
CN113164595A true CN113164595A (zh) 2021-07-23

Family

ID=63713787

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980076451.4A Pending CN113164595A (zh) 2018-09-21 2019-09-20 抗人cd45rc抗体及其用途

Country Status (13)

Country Link
US (2) US12168694B2 (https=)
EP (2) EP3626265A1 (https=)
JP (2) JP7796531B2 (https=)
KR (1) KR20210070303A (https=)
CN (1) CN113164595A (https=)
AU (1) AU2019343746C1 (https=)
BR (1) BR112021005276A2 (https=)
CA (1) CA3113562A1 (https=)
IL (1) IL281608B2 (https=)
MX (1) MX2021003281A (https=)
NZ (1) NZ774030A (https=)
SG (1) SG11202102659RA (https=)
WO (1) WO2020058495A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof
CA3172120A1 (en) * 2020-03-20 2021-09-23 Inserm (Institut De La Sante Et De La Recherche Medicale) Chimeric antigen receptor specific for human cd45rc and uses thereof
WO2023041717A1 (en) 2021-09-16 2023-03-23 Aboleris Pharma Anti-human cd45rc binding domains and uses thereof
WO2023118608A1 (en) 2021-12-23 2023-06-29 Universität Basel Discernible cell surface protein variants of cd45 for use in cell therapy
JP2026500540A (ja) 2022-12-23 2026-01-07 シメイオ セラピューティクス アーゲー Ｃｄ４５を標的とする抗体

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016442A1 (en) * 2014-08-01 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
CN107849141A (zh) * 2015-07-16 2018-03-27 Ucb生物制药私人有限公司 结合cd45的抗体分子

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
EP1690934A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69232137T2 (de) 1991-11-25 2002-05-29 Enzon Inc Multivalente antigen-bindende proteine
US5635483A (en) 1992-12-03 1997-06-03 Arizona Board Of Regents Acting On Behalf Of Arizona State University Tumor inhibiting tetrapeptide bearing modified phenethyl amides
US5780588A (en) 1993-01-26 1998-07-14 Arizona Board Of Regents Elucidation and synthesis of selected pentapeptides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
SE9400088D0 (sv) 1994-01-14 1994-01-14 Kabi Pharmacia Ab Bacterial receptor structures
US5663149A (en) 1994-12-13 1997-09-02 Arizona Board Of Regents Acting On Behalf Of Arizona State University Human cancer inhibitory pentapeptide heterocyclic and halophenyl amides
EP1176195B1 (en) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Method for controlling the activity of immunologically functional molecule
FR2807767B1 (fr) 2000-04-12 2005-01-14 Lab Francais Du Fractionnement Anticorps monoclonaux anti-d
CN1487996B (zh) 2000-11-30 2010-06-16 米德列斯公司 用于生产人类抗体的转基因转染色体啮齿动物
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
SI1545613T1 (sl) 2002-07-31 2011-11-30 Seattle Genetics Inc Avristatinski konjugati in njihova uporaba za zdravljenje raka avtoimunske bolezni ali infekcijskebolezni
US7498298B2 (en) 2003-11-06 2009-03-03 Seattle Genetics, Inc. Monomethylvaline compounds capable of conjugation to ligands
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
AU2005218642B2 (en) 2004-03-02 2011-04-28 Seagen Inc. Partially loaded antibodies and methods of their conjugation
WO2006132670A2 (en) 2004-11-12 2006-12-14 Seattle Genetics, Inc. Auristatins having an aminobenzoic acid unit at the n terminus
EP1898529A1 (en) 2005-06-28 2008-03-12 Pioneer Corporation Broadcast receiving apparatus, interference detecting apparatus and interference detecting method
HUE035853T2 (en) 2005-07-18 2018-05-28 Seattle Genetics Inc Beta-glucuronide-linker-drug conjugates
EP1929073A4 (en) 2005-09-27 2010-03-10 Amunix Inc PROTEIN MEDICAMENT AND ITS USE
KR20080068089A (ko) 2005-10-21 2008-07-22 지티씨바이오쎄라퓨틱스,인크. 항체 의존성 세포 독성 활성이 증강된 항체, 그 생산 및사용 방법
DK2602323T3 (en) 2007-06-01 2018-04-16 Open Monoclonal Tech Inc Compositions and Methods for Inhibiting Endogenous Immunoglobin Genes and Producing Transgenic Human Idiotypic Antibodies
US20120258496A1 (en) 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
FR3003171B1 (fr) 2013-03-15 2015-04-10 Lab Francais Du Fractionnement Nouveaux medicaments comprenant une composition d'anticorps enrichie en isoforme de charge majoritaire
EP3498293A1 (en) 2017-12-15 2019-06-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Treatment of monogenic diseases with an anti-cd45rc antibody
EP3626265A1 (en) * 2018-09-21 2020-03-25 INSERM (Institut National de la Santé et de la Recherche Médicale) Anti-human cd45rc antibodies and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016016442A1 (en) * 2014-08-01 2016-02-04 INSERM (Institut National de la Santé et de la Recherche Médicale) An anti-cd45rc antibody for use as drug
CN107849141A (zh) * 2015-07-16 2018-03-27 Ucb生物制药私人有限公司 结合cd45的抗体分子

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
ELODIE PICARDA ET AL: "Transient antibody targeting of CD45RC induces transplant tolerance and potent antigen-specific regulatory T cells", JCI INSIGHT, vol. 2, no. 3, 9 February 2017 (2017-02-09), pages 1, XP055601701, DOI: 10.1172/jci.insight.90088 *
刘彤等: "大鼠小肠移植后外周血CD45RC~+细胞和CD45RC~-细胞比值的变化及意义", 中华器官移植杂志, vol. 26, no. 07, 20 January 2006 (2006-01-20), pages 404 - 407 *

Also Published As

Publication number Publication date
JP2025164963A (ja) 2025-10-31
EP3852802A1 (en) 2021-07-28
BR112021005276A2 (pt) 2021-07-13
KR20210070303A (ko) 2021-06-14
JP2022502024A (ja) 2022-01-11
US12168694B2 (en) 2024-12-17
IL281608B1 (en) 2025-12-01
AU2019343746B2 (en) 2025-12-04
WO2020058495A1 (en) 2020-03-26
AU2019343746C1 (en) 2026-04-02
MX2021003281A (es) 2021-08-11
AU2019343746A1 (en) 2021-04-15
SG11202102659RA (en) 2021-04-29
NZ774030A (en) 2026-03-27
US20220033500A1 (en) 2022-02-03
US20250122300A1 (en) 2025-04-17
CA3113562A1 (en) 2020-03-26
IL281608A (en) 2021-05-31
EP3626265A1 (en) 2020-03-25
JP7796531B2 (ja) 2026-01-09
IL281608B2 (en) 2026-04-01

Similar Documents

Publication Publication Date Title
KR102761792B1 (ko) B7-h4 항체 및 그의 사용 방법
KR101527297B1 (ko) 4-1ｂｂ 결합 분자
CN113164595A (zh) 抗人cd45rc抗体及其用途
KR102405278B1 (ko) Alk7 결합 단백질 및 이들의 용도
JP2004531263A (ja) 特異的結合タンパク質およびその使用
KR20200085940A (ko) 시알릴-루이스 ａ에 대한 사람 항체 코드화 핵산
KR20230152062A (ko) 항tslp 항체를 포함하는 의약 조성물
KR20200123170A (ko) B7-h4 항체 제형
CN111868089B (zh) B7-h4抗体给药方案
KR20160131082A (ko) Lg1-3에 특이적인 항-라미닌4 항체
CN112552406B (zh) 抗人cd73抗体
CN112574313B (zh) 抗cd73抗体及其用途
EP4393949A1 (en) Pharmaceutical composition containing fusion protein
RU2826421C2 (ru) Выделенное антитело к CD45RC человека, нуклеиновая кислота, вектор экспрессии, клетка, фармацевтическая композиция, их применение, in vitro способ обнаружения hCD45RC
TWI915520B (zh) 含抗tslp抗體的藥物組合物
HK40097033A (zh) 含抗tslp抗体的药物组合物
HK40097033B (zh) 含抗tslp抗体的药物组合物
HK40091337A (zh) 针对白介素-22的抗体
HK40036127B (zh) B7-h4抗体给药方案
HK40027698B (zh) B7-h4抗体及其使用方法

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination